NO984084D0 - 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof - Google Patents
4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereofInfo
- Publication number
- NO984084D0 NO984084D0 NO984084A NO984084A NO984084D0 NO 984084 D0 NO984084 D0 NO 984084D0 NO 984084 A NO984084 A NO 984084A NO 984084 A NO984084 A NO 984084A NO 984084 D0 NO984084 D0 NO 984084D0
- Authority
- NO
- Norway
- Prior art keywords
- amino
- compounds
- preparation
- pyrimidine derivatives
- medicaments containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1996108631 DE19608631A1 (en) | 1996-03-06 | 1996-03-06 | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
| DE19629652A DE19629652A1 (en) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
| PCT/EP1997/001057 WO1997032881A1 (en) | 1996-03-06 | 1997-03-03 | 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO984084L NO984084L (en) | 1998-09-04 |
| NO984084D0 true NO984084D0 (en) | 1998-09-04 |
Family
ID=26023531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO984084A NO984084D0 (en) | 1996-03-06 | 1998-09-04 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0885226A1 (en) |
| JP (1) | JP2000506847A (en) |
| KR (1) | KR19990087550A (en) |
| CN (1) | CN1212695A (en) |
| AU (1) | AU710274B2 (en) |
| BG (1) | BG102708A (en) |
| BR (1) | BR9708312A (en) |
| CA (1) | CA2243994A1 (en) |
| CZ (1) | CZ281798A3 (en) |
| DE (1) | DE19629652A1 (en) |
| EE (1) | EE9800277A (en) |
| HU (1) | HUP9901820A3 (en) |
| IL (1) | IL125404A0 (en) |
| NO (1) | NO984084D0 (en) |
| NZ (1) | NZ331546A (en) |
| PL (1) | PL328771A1 (en) |
| SK (1) | SK120598A3 (en) |
| TR (1) | TR199801749T2 (en) |
| WO (1) | WO1997032881A1 (en) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| PT1244647E (en) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS |
| CA2530023A1 (en) | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2006088836A2 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| MX2011004824A (en) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Use of catecholic butane derivatives in cancer therapy. |
| CN102216299B (en) * | 2008-12-01 | 2015-02-11 | 默克专利有限公司 | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519282A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
| CA2780875A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
| AU2012321248A1 (en) | 2011-09-30 | 2014-04-24 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| CA2941010A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
| EP2976085A1 (en) | 2013-03-21 | 2016-01-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| EP3237638B1 (en) | 2014-12-24 | 2020-01-15 | F.Hoffmann-La Roche Ag | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| MX2019007643A (en) | 2016-12-22 | 2019-09-09 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer. |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| EP4403175A3 (en) | 2017-09-08 | 2024-10-02 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| AU2019262599B2 (en) | 2018-05-04 | 2023-10-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP3790886B1 (en) | 2018-05-10 | 2024-06-26 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| CA3099799A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| JP2022512584A (en) | 2018-10-04 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | EGFR inhibitor for treating keratoderma |
| JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| MA54543A (en) | 2018-12-20 | 2022-03-30 | Amgen Inc | KIF18A INHIBITORS |
| MX2021007157A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
| AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| CN113767100A (en) | 2019-03-01 | 2021-12-07 | 锐新医药公司 | Bicyclic heteroaryl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| KR20220011670A (en) | 2019-05-21 | 2022-01-28 | 암젠 인크 | solid state form |
| AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| US20220281843A1 (en) | 2019-08-02 | 2022-09-08 | Amgen Inc. | Kif18a inhibitors |
| US20240254100A1 (en) | 2019-08-02 | 2024-08-01 | Amgen Inc. | Kif18a inhibitors |
| US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
| JP2022552873A (en) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
| US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
| AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202132314A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
| JP2023500328A (en) | 2019-11-08 | 2023-01-05 | レボリューション メディシンズ インコーポレイテッド | Bicyclic heteroaryl compound and use thereof |
| US20230192681A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| AR120456A1 (en) | 2019-11-14 | 2022-02-16 | Amgen Inc | ENHANCED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| JP2023509701A (en) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ，インコーポレイテッド | SHP2 inhibitor dosing and methods of treating cancer |
| CN115916194A (en) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| PE20240327A1 (en) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | HETEROCYCLES WITH AMINO SUBSTITUTION TO TREAT CANCERS WITH EGFR MUTATIONS |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117616031A (en) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | RAS inhibitors for the treatment of cancer |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| DE4431867A1 (en) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | New 4-amino-pyrimido-pyrimidine derivs. |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/en not_active Ceased
-
1997
- 1997-03-03 IL IL12540497A patent/IL125404A0/en unknown
- 1997-03-03 EP EP97907066A patent/EP0885226A1/en not_active Ceased
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/en unknown
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/en unknown
- 1997-03-03 CN CN97192787A patent/CN1212695A/en active Pending
- 1997-03-03 PL PL97328771A patent/PL328771A1/en unknown
- 1997-03-03 NZ NZ331546A patent/NZ331546A/en unknown
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/en not_active Application Discontinuation
- 1997-03-03 BR BR9708312A patent/BR9708312A/en not_active IP Right Cessation
- 1997-03-03 SK SK1205-98A patent/SK120598A3/en unknown
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/en not_active Application Discontinuation
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/en unknown
- 1997-03-03 EE EE9800277A patent/EE9800277A/en unknown
- 1997-03-03 JP JP9531444A patent/JP2000506847A/en active Pending
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/en unknown
- 1998-09-04 NO NO984084A patent/NO984084D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ331546A (en) | 2000-03-27 |
| JP2000506847A (en) | 2000-06-06 |
| AU710274B2 (en) | 1999-09-16 |
| HUP9901820A2 (en) | 1999-09-28 |
| EE9800277A (en) | 1999-02-15 |
| CN1212695A (en) | 1999-03-31 |
| CZ281798A3 (en) | 1999-02-17 |
| BG102708A (en) | 1999-09-30 |
| CA2243994A1 (en) | 1997-09-12 |
| KR19990087550A (en) | 1999-12-27 |
| IL125404A0 (en) | 1999-03-12 |
| NO984084L (en) | 1998-09-04 |
| EP0885226A1 (en) | 1998-12-23 |
| BR9708312A (en) | 1999-08-03 |
| WO1997032881A1 (en) | 1997-09-12 |
| AU1925197A (en) | 1997-09-22 |
| HUP9901820A3 (en) | 2001-10-29 |
| PL328771A1 (en) | 1999-02-15 |
| TR199801749T2 (en) | 1998-12-21 |
| SK120598A3 (en) | 1999-06-11 |
| DE19629652A1 (en) | 1998-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO984084D0 (en) | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof | |
| NO940261D0 (en) | 5-Jointed Heterocycles, Methods of Preparation thereof, and Drugs Containing These Compounds | |
| NO20002835L (en) | 2-aryl-oxodihydropurine derivatives, process for the preparation of these medicinal preparations containing them, and intermediates therefor | |
| NO984082L (en) | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and method of preparation thereof | |
| NO20016185D0 (en) | Bicyclic heterocycles, drugs containing these compounds, their use and method of preparation of | |
| NO973479L (en) | Substituted heterocyclic compounds, method of preparation and pharmaceutical compositions containing the same | |
| NO20032726D0 (en) | Quinazoline derivatives, medicaments containing these compounds, their use and method of preparation thereof | |
| EE04399B1 (en) | Spiroazabicyclic Heterocyclic Compounds, Process for their Preparation, Pharmaceutical Compositions Containing Them and Their Use in Therapy | |
| NO954239D0 (en) | Heterocyclic compounds and their preparation and use | |
| DK32286D0 (en) | PROCEDURE FOR THE PREPARATION OF 1-SUBSTITUTED ARYL-1,4-DIHYDRO-4-OXANAPHTHYRIDINE DERIVATIVES, INTERMEDIATES FOR USE IN THE PROCEDURE AND PROCEDURES FOR THE PREPARATION OF THESE | |
| NO306401B1 (en) | Oxazolidinedione derivatives, pharmaceutical preparations containing such derivatives, and their use | |
| NO984081D0 (en) | Pyrimido, 5,4-d | pyrimidines, medicaments containing these compounds, their use and method of preparation thereof | |
| DK1112251T3 (en) | Acetidine derivatives, their preparation and drugs containing these derivatives | |
| NO20006251D0 (en) | Benzothiepine-1,1-dioxide derivatives, process for their preparation, medicaments containing these compounds and their use | |
| NO961071D0 (en) | Chemical compounds, their preparation and use | |
| NO20003067D0 (en) | Antipicornavirus compounds and methods for their use and preparation | |
| NO980720D0 (en) | Pyridazine-3-one derivatives, their use and intermediates for their preparation | |
| NO20000294D0 (en) | Derivatives of acylpiperazinylpyrimidines, their preparation and use as pharmaceuticals | |
| NO20003070L (en) | Substituted thiazolidine derivative, method of preparation and use thereof | |
| DK394489A (en) | IN THE PARA POSITION, HETEROCYCLIC SUBSTITUTED N-PHENYLAMIDE COMPOUNDS, INTERMEDIATES IN THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THE COMPOUNDS AND USE OF THE COMPOUNDS FOR THE CONNECTIONS | |
| DK1117661T3 (en) | Propanolamine derivatives substituted with heterocyclic groups, process for their preparation, pharmaceutical preparations containing these compounds and their use | |
| DK155292D0 (en) | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | |
| NO985248L (en) | Indolylpyrrolidene methylpyrrole derivatives and process for their preparation | |
| DK0838469T3 (en) | 10,13,15-Trioxatricyclo (9.2.1 9.6) -pentadecanone derivatives, process for their preparation, and drugs containing these compounds | |
| DK60593D0 (en) | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE |